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Abstract  Word Count: 250 
We aimed to assess if the outcome of primary prevention implantable cardioverter 
defibrillators (ICDs) without cardiac resynchronization therapy (CRT) is dependent on New York 
Heart Association (NYHA) class. Among the participants of Défibrillateur Automatique 
Implantable-Prévention Primaire (DAI-PP;NCT01992458) multicenter cohort study, 155 
patients in NYHA class I, 504 in NYHA class II and 188 in NYHA class III had a QRS width <120ms 
and were implanted with an ICD without CRT, and thus were eligible for the purpose of this 
analysis. Total and specific mortalities, and the incidence of appropriate therapies were 
assessed for every NYHA. During 2,606 patient-years (3.1±2.1 years), 104 (12.3%) individuals 
died and 188 (22.2%) experienced appropriate therapies. After adjustment, overall mortality 
increased with NYHA class (adjusted HR=1.63, 95%CI 1.11-2.41, P=0.014), driven by an increase 
in cardiovascular death. Conversely, incidence of appropriate ICD intervention was comparable 
among the 3 NYHA groups (NYHA class I 7.43, NYHA class II 7.91 and NYHA class III 12.10 per 
100 patient-years; HR=1.19, 95%CI 0.89-1.59, P=0.231). Incidence of ICD-unresponsive sudden 
death was very low and also comparable (NYHA class I 0.22, NYHA class II 0.36, and NYHA class 
III 0.83 per 100 patient-years; (HR=6.34, 95%CI 0.32-124.49, P=0.224). No significant 
differences were observed in the other specific modes of death. In conclusion, even though 
patients in NYHA class III have higher overall mortality, they experience a comparable 
incidence of appropriate ICD therapies. The low incidence of ICD-unresponsive sudden death 
in all assessed NYHA classes also supports the efficacy of ICDs, irrespective of NYHA class.  




Implantable cardioverter defibrillators (ICDs) are a proven lifesaving therapy and their use in 
the primary prevention setting is supported by Guidelines [1-2]. According to these, ICDs meet 
a class I recommendation, level of evidence A, for primary prevention in individuals on optimal 
medical therapy who are at least 40 days post-myocardial infarction and with a left ventricular 
ejection fraction (LVEF) ≤ 35%, and New York Heart Association functional class (NYHA) II or III 
symptoms. For non-ischemic cardiomyopathy, there is a class I recommendation for individuals 
with LVEF ≤ 35% and NYHA II or III symptoms, but level of evidence B only [1, 2]. However, 
while evidence supporting a 30%-35% LVEF cut-off and a 40-day time-interval post-acute 
myocardial infarction is strong and based on the results of randomized controlled trials [3-6], 
the same cannot be said for using NYHA class III, as sub-analyses of the SCD-HeFT [3] and 
MADIT-II [4] trials failed to confirm a mortality benefit of primary prevention ICD in this group 
of patients. This may imply a lack of benefit in these individuals due to a higher prevalence of 
comorbidity (i.e. competing-risk situation), or as a result of ICD-unresponsive sudden cardiac 
death. We aimed to address mortality (with cause of death analysis), appropriate ICD 
interventions and complications, and their possible interference with NYHA functional classes 
in a large cohort of “real life” patients.  
Methods 
Among the participants of the DAI-PP cohort (Défibrillateur Automatique Implantable-
Prévention Primaire; NCT01992458), 847 presented with narrow QRS, and were implanted 
with single or dual chamber ICDs: 155 patients in NYHA class I, 504 in NYHA class II and 188 in 
NYHA class III were eligible for the purpose of this analysis. Briefly, DAI-PP included patients 
who were ≥18 years of age at the time of ICD implantation. Overall, between 2002 and 2012, 
all patients with ischemic or non-ischemic cardiomyopathy, stable on maximally tolerated 
medical therapy, implanted with an ICD (biventricular, single or dual chamber) in the setting of 
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primary prevention in 12 French reference centers were considered and enrolled in the DAI-PP 
follow-up program. All other patients were classified as suffering from non-ischemic 
cardiomyopathy. 
Exclusion criteria included secondary prevention ICD recipients, those without 
structural heart disease (including channelopathies) or other types of structural heart disease 
(e.g. hypertrophic cardiomyopathy, non-compaction and arrhythmogenic right ventricular 
cardiomyopathy). We selected only patients with a QRS width <120ms implanted with single or 
dual chamber ICDs for this particular analysis, as evidence of benefit for patients with QRS 
width >120ms and heart failure symptoms already exists and mandates CRT-D implantation [7, 
8]. Only patients with NYHA class I-III symptoms on optimal medical therapy are eligible for 
primary prevention non-CRT ICDs, according to guidelines [1, 2], and therefore patients with 
NYHA class IV symptoms were excluded. 
The study was funded by public sources, including the French Institute of Health and 
Medical Research (INSERM) and the French Society of Cardiology, and was coordinated by 
Clinique Pasteur, Toulouse and the Paris Cardiovascular Research Center, European Georges 
Pompidou Hospital, Paris, in France. The study complied with the Declaration of Helsinki, and 
the data file of the DAI-PP study was declared to and authorized by the French data protection 
committee (Commission Nationale Informatique et Liberté, CNIL). 
All variables at the time of the procedure were defined and categorized according to 
the literature or common practice. In addition to NYHA functional class, assessed by the local 
DAI-PP investigator at the time of device implantation, we collected the aetiology of the 
underlying heart disease (ischemic or dilated cardiomyopathy). Estimated glomerular filtration 
rate (eGFR), was estimated using the Cockroft–Gault formula and categorized into 2 categories 
(≥60 and <60 mL/min). Atrial fibrillation (AF) was defined as a history of AF (paroxysmal or 
persistent), documented on standard ECG or 24-hour Holter monitoring. Co-morbidities were 
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systematically collected: cancer, chronic obstructive pulmonary disease, chronic renal failure, 
chronic liver disease, history of transient ischemic neurological attack, and others (including 
diabetes mellitus). Device programming was left to the implanting/managing physician’s 
discretion.  
Follow-up information was obtained from appointments every 4-6 months for device 
evaluation, according to French guidelines [9]. The different endpoints included occurrence of 
appropriate therapies, early complications, inappropriate shocks and overall and specific 
mortalities.  
Device interrogation data were checked by local investigators for appropriate and 
inappropriate ICD therapies. Appropriate ICD therapy was defined as an episode of ventricular 
tachycardia/ventricular fibrillation resulting in a single or multiple shocks and/or anti-
tachycardia pacing for arrhythmia termination. The date of the first appropriate ICD therapy 
was recorded, and the cumulative number of appropriate therapies. The cause of 
inappropriate shock(s) was collected. Adjudication of therapy type (appropriate or 
inappropriate) was undertaken by the local investigator.  
Early complications (defined as those appearing in the first 30 days after device 
implantation) included lead dysfunction, bleeding or hematoma, sepsis, cardiac tamponade, 
pneumothorax and death. 
Mortality data were obtained from the hospital or the general practitioner, and were 
systematically controlled through the National Institute of Statistics Economical Studies 
(INSEE). Causes of death were obtained from the investigators and/or by the French Center on 
Medical Causes of Death (CépiDc–INSERM). The CépiDc–INSERM is a public, academic 
institution focused on the analysis of circumstances and causes of death based on death 
certificate and medical records. Causes of deaths were classified according to the International 
Classification of Diseases (10th Revision). This information was reviewed by two investigators 
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and causes of death adjudicated after consideration of all available information, and according 
to the following pre-specified groups: cardiovascular (including progressive heart failure death, 
stroke), non-cardiovascular, ICD-unresponsive sudden cardiac death (SCD) (arrhythmic or non-
arrhythmic whenever assessment possible), ICD-related death, as well as unknown when the 
quality of the information could not allow investigators to appropriately identify cause of 
death. Overall, cause of death assessment was possible among 91 out of 104 deceased 
patients (87.5%). 
Preparation of this report was in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement for reporting of observational 
studies [10]. 
Comparisons were performed across the different NYHA functional class strata. Chi-
square was used for comparison of nominal variables and Student’s t-test for continuous 
variables; the Levene’s test was used to check the homogeneity of variance; when appropriate 
non-parameteric equivalent, Mann-Whitney test, was employed. When baseline differences 
were present, adjustment was performed. Results with p < 0.05 were regarded as significant. 
We compared the adjusted outcomes of appropriate shock and death across different 
NYHA class strata by using Cox proportional hazards regression analysis. Hazard-curves were 
traced for comparison of the occurrence of events among the different NYHA functional 
classes after adjustment for baseline differences. Univariate Cox Regression and subsequent 
multivariate Cox Regression (forward likelihood ratio, probability for stepwise= 0.05) was 
performed for assessment of predictors of mortality and appropriate ICD interventions. 
Data was filled into a pre-defined data introduction electronic sheet made available to 
all participant Centers. After completion of follow-up, data from all Centers was merged and 
analysed at the Paris Cardiovascular Research Center (Inserm U970, Cardiovascular 
Epidemiology Unit) using SAS program v9.3 (SAS Institute Inc, Cary, North Carolina). 
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Results 
Among the 847 patients who were deemed eligible for analysis, mean age was 
59.3±11.6 years and 13.0% (110) were female. AF was present in 15% of patients and ischemic 
cardiomyopathy was the most prevalent, accounting for almost 74% of the sample. Moderate 
to severe renal impairment (eGFR < 60ml/min) was observed in almost 30% of patients. The 
use of single and dual chamber ICDs was equally distributed (Table 1). 
No differences were observed with respect to age or gender across the three different 
NYHA functional classes. However, AF was more prevalent in NYHA III patients, but ischemic 
cardiomyopathy less prevalent compared to those in NYHA class II. NYHA I and II patients more 
frequently had no co-morbidities, and those in NYHA II and III frequently had ≥2. Left ventricle 
ejection fraction decreased as NYHA functional class progressed (Table 1).  
Assessment of medication use showed use of furosemide and vitamin-K antagonists 
was more frequent in NYHA classes II and III (a progressive and significant increase across the 
three NYHA functional classes). However, amiodarone was used almost twice as much in NYHA 
class III than those in classes I and II, while beta-blocker use was broadly similar. 
During 2,606 patient-years of follow-up (mean of 3.1±2.1 years), 188 (22.2%) 
individuals experienced at least one appropriate therapy (anti-tachycardia pacing or shocks), 
with annual incidence rates of 7.43 (95%CI 5.25-10.41), 7.91 (95%CI 6.61-9.44), and 12.10 
(95%CI 9.22-15.72) per 100 patient-years, in NYHA classes I, II, and III, respectively (Table 2). 
After adjustment for baseline differences among the three NYHA classes, the likelihood of 
appropriate ICD intervention was comparable (HR = 1.19, 95%CI 0.89-1.59, P=0.231) (Figure 1). 
The percentage of patients with appropriate therapies across the 3 classes was similar, and 
these occurred at least once in every four or five implanted patients (NNT = 5 in NYHA I, 4.4 in 
NYHA II, and 4 in NYHA III) (Table 2). The occurrence of inappropriate shocks, complications, 
and box change as a result of battery depletion was comparable among the three groups.  
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Few patients (3.3%; n=28) were lost to follow-up, either because they had their follow-
up transferred to other centers or moved out of the country. A total of 104 (12.3%) individuals 
died during follow-up. Mortality progressively increased from 1.73 per 100 (95%CI 0.88-3.37) 
patient-years in class I, to 3.79 (95% 2.97-4.82) in class II and 6.87 (95% 4.93-9.49) in class III 
(Table II). On multivariate Cox regression, only age (HR=1.03 per increase in year, 95%CI 1.01-
1.05, P=0.006), eGFR < 60ml/min (HR=1.70, 95%CI 1.09-2.65, P=0.019) and NYHA class 
(HR=1.63 per increase in class, 95%CI 1.11-2.41, P=0.014) (Figure 1), but not appropriate 
therapies, were independent predictors of mortality.  
Incidence of death prior to receiving any appropriate therapy was similar in all NYHA 
groups: 62.5% (5 in 8 deaths) in NYHA I patients, 71.0% (44 in 62 deaths) in NYHA II patients, 
and 69.7% (10 out of 33 deaths) in NYHA III patients (P=0.889) (Figure S-1 – supplementary 
material – available online only). 
The occurrence of ICD-unresponsive sudden death, ICD-related death, and death from 
unknown causes was very low and comparable among all groups (all P=N.S.) (Table 2 and 
Figure 2). The incidence of death from refractory heart failure approximately doubled for every 
increase in NYHA functional class cohort (HR=2.01, 95%CI 1.09-3.71, P=0.026). Non-
cardiovascular mortality was numerically, but non-significantly, higher in NYHA functional class 
III patients compared to NYHA I and II. 
Discussion 
Our data suggest that even though primary prevention ICD patients in NYHA class III 
who are not candidates for CRT have higher global mortality than their healthier counterparts 
in lower NYHA classes, they seem to experience a comparable incidence of appropriate ICD 
interventions. No excess in inappropriate shocks or early complications was observed in the 
more symptomatic patients’ NYHA class. This suggestion of a comparable net benefit 
independently of NYHA class was observed in spite of the presence of more severe and 
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advanced disease, and more comorbidities in NYHA class III patients. The incidence of death 
from refractory heart failure doubled for every increase in NYHA functional class. Incidence of 
ICD-unresponsive sudden death in primary prevention ICD recipients is very low and similar 
across NYHA class, suggesting that ICD therapy can prevent this outcome as effectively in those 
with NYHA functional class III symptoms as those with less symptoms. To the best of our 
knowledge, this is the first cause of death analysis according to NYHA class in a primary 
prevention ICD setting.  
A recent meta-analysis on the therapeutic efficacy of common heart failure 
interventions according to NYHA status, including trial data only, has suggested that relative 
mortality reduction with most interventions was independent of baseline NYHA class [11]. 
However, that did not seem to apply to ICDs, whose efficacy was greater in individuals with 
lower NYHA (classes I and II vs. classes III and IV). Conversely, these results are challenged by a 
previous meta-analysis, including non-CRT ICD trials only, which shows no evidence of a 
tendency for the relative risk reduction to be smaller in patients with severe heart failure [12]. 
We believe these meta-analyses are difficult to interpret, as they have several caveats: in the 
first [11], ICD and CRT-D trials are combined, and comparisons are performed which include 
NYHA class IV individuals, where the use of primary prevention ICDs is debatable; in the 
second [12], primary and secondary prevention ICD trials were pooled together, mixing two 
very different subsets of patients with very different inherent risks. 
Trials in the pre-ICD era, like the “Metoprolol CR/XL Randomised Intervention Trial in 
Congestive Heart Failure” (MERIT-HF) have shown that, in patients treated medically, sudden 
death accounted for the majority of deaths in patients in NYHA classes II and III (64% and 50%, 
respectively) [13]. In the present analysis with patients treated with primary prevention ICDs, 
sudden cardiac death accounted for only approximately 10% of all deaths, across all assessed 
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NYHA functional classes, clearly indicating a paradigm shift in prognosis for these patients, who 
now die more frequently due to pump failure or non-cardiac causes.  
Other groups have shown that primary prevention ICD patients with more advanced 
NYHA class have a higher, or at least similar, incidence of appropriate ICD therapies [14-16]. 
Kreuz et al. [14] and Zareba et al. [15], in 2 studies comprising only non-CRT ICDs recipients, 
have shown that patients in more advanced NYHA class experience higher rates of appropriate 
therapies. Ng and colleagues, in a cohort of primary prevention ischemic cardiomyopathy 
patients including 62% with CRT-Ds, found that NYHA class was not a predictor for appropriate 
interventions [16]. These last results, resemble our own findings, where appropriate therapies 
occurred at a similar rate, irrespective of NYHA functional class. 
Appropriate ICD therapies have previously been associated with increased risk of 
mortality by other groups [17-19]. However, in this cohort of primary prevention ICD 
recipients, the occurrence of appropriate therapies was not a predictor of death, even when all 
NYHA classes were assessed separately. This evidence does not support the view (perhaps 
pessimistic) that ICD therapy lacks survival benefit in the NYHA class III population. Similarly, 
even though patients in class III present with a higher prevalence of co-morbidity and may 
ultimately die from advanced heart failure or other non-cardiac competing causes, these data 
show that the incidence of sudden death is very low and comparable across all NYHA groups, 
suggesting ICD therapy prevents sudden death as effectively in NYHA class III patients when 
compared to healthier patients. It has been previously suggested that patients in more 
advanced stages of disease, with higher number of comorbidities may potentially be too sick to 
derive benefit from this lifesaving therapy, and would die irrespective of receiving appropriate 
therapies [18]. Data from this analysis does not support this hypothesis. 
Lastly, NYHA is an established and well-validated predictor of mortality in the ICD 
population, as observed in our analysis, and its use has been suggested as part of calculating 
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risk scores [20, 21]. However, the causes and mechanisms of death in these patients are not 
clearly understood, as most studies assessing this issue thus far, do not provide a detailed 
cause of death analysis. The score proposed by Goldenberg and colleagues, derived from the 
MADIT-II trial, suggests that individuals in higher NYHA classes may still derive a benefit from 
ICD therapy, as long as they don’t possess two or more additional risk factors, which can lead 
to death due to non-cardiac competing causes and other comorbidity [20]. 
This analysis has a number of limitations that should be highlighted. Firstly, device 
programming was left to the discretion of individual investigators, according to each patient’s 
needs, may have been a source of some inter-individual variability. This factor has been 
minimized by proposed programming rules particularly based on using high detection windows 
and not suggesting specific adjustments according to NYHA functional class [9]. Secondly, data 
was collected only for overall appropriate ICD therapies and not specifically for anti-
tachycardia pacing or shocks. Therefore, a separate analysis cannot be performed for therapy 
type. Thirdly, no post-mortem ICD interrogation was performed routinely to help confirm 
mode of death, meaning we do not know the incidence of unsuccessful ICD therapies 
preceding death. Fourthly, no central adjudication for classification of appropriate and 
inappropriate therapies was used in this registry.  Lastly, NYHA class may have changed 
significantly during the long-term follow-up. Unfortunately, this information was not available. 
Therefore, the main focus of this analysis was NYHA class at the time of device 
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Figure 1 – Mortality and incidence of appropriate ICD interventions during follow-up. 
 
Legend: NYHA – New York Heart Association functional class. Adjustment performed for baseline differences (atrial 




Figure 2 – Causes of death (relative %) according to NYHA functional class. 
  
Legend: NYHA – New York Heart Association functional class; ICD – implantable cardioverter defibrillator; CV – 
cardiovascular.  
